• Microplastics, Nanoplastics, and Pulmonary Fibrosis

  2026-08-25

  A 2026 Toxicology study compared polystyrene, polyethylene, and polypropylene particles across micro- and nanoscale size classes in mouse and BEAS-2B lung models. The results identify stronger toxicity for polystyrene nanoplastics and implicate dysregulation of the FXR–YAP1 axis in fibrotic and inflammatory responses.

• Imipenem Workflows for Resistance Research

  2026-08-25

  Imipenem supports more than routine antibacterial testing: it can connect susceptibility phenotyping with carbapenemase transmission studies and immune-response assays. This workflow-focused guide shows how to use the compound in isolate characterization, plasmid-transfer experiments, and carefully bounded sepsis animal model research.

• TMEM16F in Kupffer Cells Limits Listeria Liver Injury

  2026-08-24

  This 2024 Advanced Science study identifies Kupffer cell-expressed TMEM16F as the major cell-intrinsic determinant protecting the liver during Listeria monocytogenes infection. Cell type-specific mouse models and membrane-injury assays link TMEM16F-dependent lipid scrambling and plasma-membrane repair with reduced macrophage lysis, liver inflammation, and metabolic disruption.

• MK-2206 Dihydrochloride in Akt Pathway Assays

  2026-08-23

  MK-2206 dihydrochloride provides a selective way to connect Akt phosphorylation with apoptosis, metabolic remodeling, and treatment response. This workflow-focused guide shows how to use it in cancer studies and exploratory osteogenesis assays while separating biochemical potency from cellular interpretation.

• Cirsium setidens and Doxorubicin Cardiotoxicity

  2026-08-22

  A 2024 Phytomedicine study found that hydroethanolic Cirsium setidens extract protects cardiac cells and cardiac function from doxorubicin-associated injury through an AMPK–PGC-1α–NRF1–SOD mitochondrial pathway. Its most important translational feature is the apparent separation of cardioprotection from interference with doxorubicin-induced cancer-cell apoptosis, although the evidence remains preclinical.

• Budesonide Workflows for Airway Inflammation Research

  2026-08-21

  Build reproducible Budesonide assays for asthma inflammation models, from DMSO stock preparation to biomimetic membrane screening and airway-cell validation. This workflow uses IAM LC for scalable physicochemical profiling and LEKC for more membrane-relevant pulmonary permeability insight, while clearly separating evidence from starting-point recommendations.

• DiscoveryProbe FDA-approved Drug Library Workflow

  2026-08-21

  Turn a clinically informed compound collection into a practical workflow for target-based, phenotypic, and orthogonal screening. The DiscoveryProbe FDA-approved Drug Library supports drug repositioning screening while the Tideglusib–Pif1 study demonstrates how a library hit can progress from fluorescence polarization to mechanism.

• Hypoxia and Immunometabolism in the Tumor Microenvironment

  2026-08-20

  This review explains how oxygen deprivation and nutrient competition jointly reprogram tumor and immune-cell behavior within the tumor microenvironment. Its central contribution is an integrated framework linking HIF signaling, altered glucose metabolism, immune dysfunction, and therapeutic opportunities while emphasizing the dynamic feedback that sustains immunosuppression.

• VER 155008: HSP 70 Inhibitor Workflows

  2026-08-20

  VER 155008 enables mechanism-focused studies of Hsp70 ATPase inhibition, chaperone-dependent apoptosis, and cancer cell proliferation inhibition. This guide connects biochemical assay design with cellular validation and a carefully bounded application to TDP-43 phase-separation research.

• SVA 3A/2B Target DDX23 Through Caspases

  2026-08-19

  The reference study identifies a reciprocal antiviral interaction in which host helicase DDX23 restricts Senecavirus A (SVA) through caspase-dependent degradation of viral 3A, while viral 2B promotes DDX23 loss. Protein perturbation, inhibitor experiments, residue mapping, and reverse genetics connect these mechanisms to specific amino acids and viral replication, although the findings remain primarily validated in a cell-based SVA model.

• Metoprolol: Exposure-Aware Research Design

  2026-08-19

  Metoprolol is a selective beta1-adrenoceptor antagonist with applications spanning cardiovascular disease research and exploratory inflammation, cancer, and angiogenesis studies. This article presents an exposure-aware assay strategy inspired by integrated pharmacokinetic and tissue-distribution research in MASH models.

• Indomethacin (A8449): Practical Research Guide

  2026-08-18

  Indomethacin (SKU A8449) provides a defined small-molecule perturbation for inflammation research and related lipid or membrane studies, with dossier-reported Cox-1/Cox-2 inhibition and additional PPAR activity. Because it is water-insoluble and its solutions are not intended for long-term storage, it should be used with a validated DMSO or ethanol workflow rather than in aqueous-only systems.

• 4-Ethylphenyl Sulfate in Cell Assays

  2026-08-18

  Learn how SKU B6051, 4-Ethylphenyl sulfate, can support controlled cell viability, proliferation, and cytotoxicity workflows linked to renal and gut-brain biology. This scenario-based guide emphasizes solvent controls, exposure calculations, assay-interference checks, and evidence-based product selection.

• Vorinostat: HDAC Workflows for Apoptosis Research

  2026-08-17

  Build reproducible Vorinostat assays that connect HDAC inhibition with chromatin remodeling, mitochondrial apoptosis, and transcription-linked stress signaling. This practical guide combines dose-response design, orthogonal readouts, and the latest RNA Pol II findings to improve interpretation in cancer biology research.

• CSBTA Pharmacokinetics in MASH Mice

  2026-08-16

  The reference study shows that HFHCD-induced MASH-like pathology changes the systemic exposure, hepatic distribution, and hepatocyte accumulation of major Corydalis saxicola Bunting total alkaloids. By combining UHPLC-MS/MS profiling with transporter, microsomal metabolism, and PXR-related analyses, it links disease-state pharmacokinetic variability to altered CYP450, Oatp1b2, and P-gp function, providing a rationale for disease-adjusted dosing research.

452 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page